Although whole-parasite vaccine strategies for malaria infection have regained attention, their immunological mechanisms of action remain unclear. We find that immunization of mice with a crude blood stage extract of the malaria parasite Plasmodium falciparum elicits parasite antigen-specific immune responses via Toll-like receptor (TLR) 9 and that the malarial heme-detoxification byproduct, hemozoin (HZ), but not malarial DNA, produces a potent adjuvant effect. Malarial and synthetic (s)HZ bound TLR9 directly to induce conformational changes in the receptor. The adjuvant effect of sHZ depended on its method of synthesis and particle size. Although natural HZ acts as a TLR9 ligand, the adjuvant effects of synthetic HZ are independent of TLR9 or the NLRP3-inflammasome but are dependent on MyD88. The adjuvant function of sHZ was further validated in a canine antiallergen vaccine model. Thus, HZ can influence adaptive immune responses to malaria infection and may have therapeutic value in vaccine adjuvant development.
INTRODUCTION
Whole-microbe vaccines have been successful in preventing and/or treating many infectious diseases, by harboring not only protective antigens, but also ''built-in'' adjuvant components capable of activating the innate immune system (Pulendran and Ahmed, 2006; Ishii et al., 2008; Palm and Medzhitov, 2009 ). In the case of malaria, there is evidence that host protective immunity against blood stage malaria parasites can be achieved in humans as well as in animal models following whole-parasite vaccinations, although large numbers of parasites are required (Good, 2009; Doolan et al., 2009 ). Among parasite-derived molecules, potentially protective antigens have been investigated intensively for vaccine development (Girard et al., 2007; Coppel, 2009 ). However, the adjuvant components within blood stage parasites have not been explored; likely adjuvant components include ligands for innate immune receptors, such as Toll-like receptors (TLRs), NOD-like receptors (NLRs), and RIG-I-like receptors (Stevenson and Riley, 2004; Coban et al., 2007a) .
There are several candidate molecules in Plasmodium parasites that could act as adjuvant components (Schofield et al., 2002; Pichyangkul et al., 2004; Krishnegowda et al., 2005; Coban et al., 2005; Parroche et al., 2007; Seixas et al., 2009 ). TLR2 and TLR9 have been shown to mediate innate immune system activation by GPI, a heat-labile fraction, and hemozoin (HZ) and DNA derived from Plasmodium falciparum (Pf) (Krishnegowda et al., 2005; Pichyangkul et al., 2004; Coban et al., 2005; Parroche et al., 2007) ; however, discrepancies among these findings remain unresolved (Coban et al., 2007a) . TLR9 has also been proposed to play important roles in the pathogenesis of cerebral malaria by recruiting immune cells into the brain (Coban et al., 2007b; Griffith et al., 2007) , or in that of severe malaria owing to the induction of regulatory T cells and/or synergy with interferon g (IFNg) signaling (Hisaeda et al., 2008; Franklin et al., 2009 ), but this is also controversial with some reports suggesting that this is not the case (Lepenies et al., 2008; Togbe et al., 2007) . In addition, recent reports suggest that uric acid is released during malaria infection (Orengo et al., 2008) , thereby activating the innate immune system presumably via NLRs, particularly NLRP3 (also known as NALP3) and its adaptor molecule apoptosis-associated speck-like protein containing a CARD domain (ASC), leading to caspase-1 activation (Franchi et al., 2009) .
We therefore investigated further whether TLRs, and TLR9 in particular, as well as other innate immune receptors such as NLRs, are involved in Pf-mediated innate and adaptive immune responses, and whether HZ plays any role in such adaptive immune responses. We found that Pf whole-parasite crude extracts elicit parasite antigen-specific adaptive immune responses via TLR9, but not via NLRP3 or ASC. The malarial product HZ showed a potent adjuvant effect without any requirement for DNA. Further analysis at the molecular and atomic levels revealed that TLR9 binds to HZ directly and specifically, in a manner that depends on particular motifs and amino acid sequences, similar to its binding of CpG DNA, a well-known TLR9 ligand. A synthetic version of HZ also displayed a strong adjuvant effect; however, its optimal response was quite variable and dependent on its method of synthesis as well as its structural appearance.
RESULTS
A Pf Crude Extract Contains a TLR9 Ligand as a Built-in Adjuvant for Coadministered Malaria Antigens To examine the possible adjuvant effects of whole parasites, we prepared a large quantity of whole-parasite antigens by freezethawing of Pf-infected red blood cells. The resulting extract, designated the Pf crude extract, contained products from both parasites and host red blood cells was immunized into mice. Three weeks after immunization, without any additional adjuvant, a significantly higher titer of serum Pf crude extract-specific immunoglobin G (IgG) was detected compared with the titers in naive mice and mice immunized with a normal red blood cell extract, in a dose-dependent manner ( Figure 1A and data not shown). The antibody titers were 10 times higher after boost immunizations ( Figure 1D ).
We subsequently examined whether the immunogenicity of the whole-parasite vaccine was altered in the absence of TLR9, because TLR9 has been shown to mediate innate immune system activation by a heat-labile fraction, HZ and DNA derived from Pf (Coban et al., 2007a) . Accordingly, mice lacking TLR9 showed significantly lower serum IgG (mainly IgG2c) responses and T-cell-specific IFNg levels than wild-type mice ( Figures 1A-1C ). This TLR9-dependent adjuvant effect of whole-parasite antigens was specific for the immunizing Pf antigens, such as Pf SERA5 and Pf MSP1 ( Figure 1F and data not shown). TLR9-dependent IgG responses were also observed for IgG2b and IgG3, but not for IgG1 (see Figures S1A-S1C available online). These data clearly demonstrate that Pf crude extract possesses a TLR9 ligand as a built-in adjuvant for coadministered malaria antigens.
The ASC-Inflammasome Is Not Involved in the Adjuvant Effect of Pf Crude Extract We next investigated whether the inflammasome and its components were involved, given the fact that Plasmodium parasites grown in erythrocytes increase the concentration of uric acid, a known NLRP3 ligand that acts as a ''danger signal'' and activates the ASC-inflammasome (Orengo et al., 2008) . Moreover, recent studies suggest that DNA from any living organism may activate the ASC-inflammasome, independently of TLR9 (Muruve et al., 2008; Takeshita and Ishii, 2008) , and that this may be mediated by AIM2 (Roberts et al., 2009; Hornung et al., 2009; Fernandes-Alnemri et al., 2009; Burckstummer et al., 2009 ). However, neither ASC-nor NLRP3-deficient mice showed any reduction in the adjuvant effect of Pf crude extract ( Figures 1D and 1E ). These data suggest that the critical adjuvant activity within Pf crude extract is mediated by TLR9, but not ASC-inflammasome.
Pf DNA Is Not Involved in the Adjuvant Effect of Pf Crude Extract What components of the malaria parasite are responsible for the TLR9-dependent adjuvant effect? Although immune recognition of malarial HZ by TLR9 has been previously demonstrated in vitro and in vivo (Coban et al., 2005) , another study suggested that HZ itself was immunologically inert, and that TLR9-dependent immune activation is instead caused by HZ-conjugated malarial DNA (Parroche et al., 2007) . To investigate whether Plasmodium DNA is responsible for the TLR9-dependent adjuvant effect of Pf crude extract, DNA was removed by DNase-I treatment. To confirm that DNA was successfully removed from Pf crude extract, we performed Pf typing polymerase chain reaction (PCR) based on the nested PCR technique (Snounou et al., 1993) , and did not find a trace of PfDNA after DNasetreatment ( Figure S2B ). After immunizations, we found that the TLR9-dependent adjuvant effect of whole-parasite antigens was not affected by DNase-I treatment (Figure 2A ), suggesting that DNA is not the TLR9-dependent adjuvant component of Pf crude extract. A ligand is defined as a molecule with affinity and specificity for binding directly to a receptor. To examine such direct interactions between TLR9 and Pf crude extract, we established an enzyme-linked immunosorbent assay (ELISA)-based binding assay. Both rTLR9 and rTLR2 showed specific interactions with their cognate ligands ( Figure S2A ), confirming previous findings (Rutz et al., 2004) . When the Pf crude extract was tested for binding to rTLR9 and rTLR2, we found that TLR9, and to a lesser extent TLR2, interacted strongly and in a dose-dependent manner with the Pf crude extract ( Figure 2B ), consistent with the findings of a previous report (Parroche et al., 2007) . However, in sharp contrast with their findings, DNase-I treatment of the Pf crude extract did not alter its interaction with rTLR9, while the same DNase-I treatment abrogated TLR9 binding to Pf genomic DNA ( Figures 2C and 2D ). Of note, in contrast to the findings of Parroche et al., several attempts using nuclease treatment of Pf crude extract with several nuclease sources, showed either no effect on Pf crude extract binding to TLR9 or even nonspecific binding to TLR9 protein (Figures S2B and data not shown). Taken together, these data clearly demonstrate that some component of the Pf crude extract acts as a TLR9 ligand, mediates adaptive immune responses through TLR9, and directly binds to rTLR9 in a specific manner, and that this interaction does not require or involve DNA.
Hemozoin Binds Specifically to and Changes the Conformation of TLR9 After eliminating the possible involvement of genomic DNA in Pf crude extract adjuvanticity, we next investigated the role of hemozoin as a possible adjuvant molecule in the Pf crude extract. Given that it is not possible to deplete hemozoin from Pf crude extract without denaturing the malarial antigens ( Figure S2C ), and that using extensively purified natural PfHZ would always be questioned on the basis of its purity, we used synthetic hemozoin derived from a highly pure source and thought to be identical to natural HZ (Pagola et al., 2000) . Competition assays were then performed to investigate whether sHZ could block the binding of TLR9 protein to Pf crude extract. TLR9 binding to the coated Pf crude extract was measured in the presence of sHZ, CpG DNA (another known TLR9 ligand) or monosodium urate crystals (MSU). MSU crystals are insoluble immunostimulatory crystals that activate the innate immune system in a TLR9-independent manner (Martinon et al., 2006) , because they form crystals that resemble sHZ in size and rod shape by surface electron microscopy ( Figure S2E ). TLR9 binding to the Pf crude extract was blocked by sHZ in a dose-dependent manner, as well as CpG DNA ( Figures 3A and 3B ). On the other hand, MSU did not alter the binding of TLR9 to Pf crude extract ( Figure 3C ). Latz et al. recently demonstrated that TLR9 protein changes its conformation upon ligation . To monitor the conformational changes in the rTLR9 protein accompanying binding of its ligands, circular dichroism (CD) measurements were performed. Specifically, the CD spectra of rTLR9 protein were measured with or without the ligands at pH 5.5. The CD spectra of rTLR9 were altered by CpG DNA and sHZ, but not MSU, in a dose-dependent manner, characterized by remarkable spectral changes with shifts of the zero crossing point ( Figures 3D-3F and Figure S2C ). We also performed similar studies with soluble hemin that showed similar pattern and changed the conformation of rTLR9 as sHZ did, but not synthetic dsRNA (poly I:C) ( Figure S2F ). Taken together, these results demonstrate that sHZ can compete with Pf crude extract for binding to rTLR9 and change its conformation in a similar manner to CpG DNA. 
Direct and Specific Interaction between Hemozoin and TLR9 Observed at the Molecular and Atomic Levels
To further clarify the nature of the interaction between TLR9 and HZ, short peptides containing unique sequences of the TLR9 extracellular domain (sequences that are specific to the TLR9 extracellular domain and not contained in the extracellular domains of the other TLR family proteins) were synthesized and screened to identify the binding site(s) for TLR9 ligands. The peptides were subjected to ELISA-based binding assays with various TLR9 ligands, namely, Pf crude extract, hemin (a single unit of HZ) and CpG DNA ( Figure 4A ). Only four peptides, all of which had unique CysXXCys or Cys motifs similar to zinc finger motifs, bound to these ligands. Cysteine was required for the binding of these peptides as revealed by the same assays using mutant peptides (in which Cys was mutated to Ser) for which the binding ability was completely abrogated ( Figure 4B ). To analyze the binding sites in the peptides at an atomic level, nuclear magnetic resonance (NMR) titration was performed with peptides and CpG DNA and hemin. Using the peptide VGGNCRRCDH, which had the highest binding to the TLR9 ligands ( Figure 4A ), and its mutant peptide, the concentration of hemin and CpG DNA was increased stepwise and the spectral changes caused by hemin and CpG DNA were followed for each, as shown in Figures S3A and S3B and in greater detail in Figures 4C and 4D . Both hemin and CpG DNA shifted a peak at a 1 H resonance frequency of 8.2 ppm and slightly shifted at 7.1 and 7.8 ppm; all peaks were broadened to a lower intensity, upon addition of increasing concentrations of hemin, although no significant broadening was observed for CpG DNA ( Figures  4C and 4D ). When we performed the same titration experiments using the mutant peptides that lack Cys, we observed no such shifts ( Figures 4C and 4D) , although a decrease in intensity still remained upon increasing the concentration of hemin. These results indicate that TLR9 binds both HZ and CpG DNA and suggest that 4 cysteine residues may play an important role in the interaction between TLR9 and its ligands. Hemozoin Acts as a Potent Adjuvant, and Its Adjuvanticity Depends on Its Size Is pure synthetic HZ a good adjuvant in vivo? Given the fact that various hemin chloride sources and methods can be used to synthesize sHZ, we first employed several production protocols to investigate the adjuvant properties of sHZ (Egan, 2008) using ultrapure hemin chloride. We found that two commonly used methods for synthesizing sHZ from hemin chloride produced crystals with a distinct appearance that differed in their adjuvant effects. With one method, HZ polymerized in the presence of acetic acid (method 1) and produced crystals that ranged in diameter from 50 nm to 1 mm, while the other method, involving an organic base (method 2), produced crystals that ranged in size from 1 to 5 mm as visualized by field emission scanning electron microscopy (FESEM) ( Figures 5A and 5B). When mice were immunized with the model protein antigens ovalbumin (OVA) (or in some cases human serum albumin [HSA]) in the presence or absence of sHZ produced by method 1 or 2, the OVA-specific total IgG responses were significantly higher with sHZ produced by method 1 than with sHZ produced by method 2 ( Figure 5C ). Interestingly, when we separated the HZ produced by method 1 into two size distributions using a laser-scattering particle size distribution analyzer ( Figure 5D ), larger sHZ particles (up to 20 mm in size) were counted. It should be noted that sHZ crystals tend to make aggregates that the larger HZ particles might be attributed to the aggregation. Nevertheless, sHZ with sizes between 50 and 200 nm had optimal adjuvant effects compared with larger sHZ molecules (2-20 mm) and the smaller hemin monomer (<50 nm) ( Figure 5E ). We also examined different administration routes to investigate the adjuvant effects of sHZ such as subcutaneous (s.c.) and intranasal (i.n.) routes, and found that antigen-specific antibody responses were induced in a dose-dependent manner (Figures S4A and S4B and Figure 6A) . There were no detectable OVA-specific IFNg or interleukin (IL)-17 production by spleen cells, but substantial amounts of OVA-specific IL-13 and IL-5 were detected (Figure S4C) . Analysis of the IgG isotypes elevated by sHZ coadministration showed that mainly IgG1 isotypes were elevated, followed by IgG2b and IgG2c, in mice ( Figure 6B ); this response was very potent when compared with those elicited by the adjuvants alum or CpG DNA ( Figure 6C ). On the other hand, sHZ administration elevated mainly IgG1 responses, while CpG DNA elevated mainly IgG2a ( Figure S4D ). Therefore, sHZ is indeed a potent adjuvant for protein vaccines, with optimal sizes of 20-200 nm, which coincide with the sizes of other particle adjuvants taken up by antigen-presenting cells via receptor-mediated endocytosis (McGee et al., 1997; Xiang et al., 2006) .
Synthetic Hemozoin's Adjuvant Effect Is Mediated by
MyD88, but Not TLR9 or the Inflammasome/IL-1b We further investigated how the HZ adjuvant effect was regulated. To examine whether the potent adjuvant effect of sHZ was mediated by TLR9 and through MyD88, mice lacking TLR9 and MyD88 were immunized with OVA plus sHZ. MyD88-deficient mice failed to elicit a serum anti-OVA antibody titer ( Figure 6D ). By contrast, however, TLR9-deficient mice showed comparable anti-OVA titers to those in wild-type mice, suggesting that there are distinct mechanisms for the adjuvant effects of sHZ other than TLR9, any of which seem to culminate in MyD88-dependent signals. We confirmed these findings by obtaining similar results with HSA ( Figures S5A and S5B ). Particles like MSU crystals have recently been shown to be recognized by NOD-like receptors (NLRP3 in the case of MSU) and form large cytosolic complexes, collectively called the inflammasome. We were interested in clarifying whether the adjuvanticity of sHZ, whose appearance resembles MSU crystals ( Figure 5A and Figure S2D ), could involve the inflammasome. In the same set of OVA or HSA immunization protocols, mice deficient in ASC or NLRP3 elicited normal antibody responses ( Figure 6E and Figure S5B ) as well as IL1R-deficient mice ( Figure 6F and Figure S5C ). These results suggest that inflammasome/ IL-1b pathway have a minimal role in the adjuvant effect of sHZ.
To examine whether sHZ-induced inflammation occurs in vivo, we measured neutrophil recruitment. When sHZ was injected intraperitoneally, significant numbers of neutrophils were recruited into the peritoneum within 24 hr ( Figure S6A ), and the neutrophil recruitment occurred normally in mice lacking either ASC or TLR9 ( Figure S6B ). However, mice lacking MyD88 failed to exhibit neutrophil recruitment in response to sHZ injection ( Figure S6A ).
Synthetic Hemozoin Is a Potent Adjuvant for Malarial Antigens as Well as for an Allergen
It has been previously shown that subclinical infection of healthy human volunteers with red cells infected with Pf or immunization of mice with a small number of dead parasites in the presence of CpG DNA or alum can induce cellular immunity and protection (Pombo et al., 2002; Good, 2009 ). To examine whether sHZ would have a potent adjuvant effect on immunization with Pf crude extract from a few parasites, we immunized mice s.c. with 10 mg total Pf crude extract together with sHZ, boosted twice, and measured anti-Pf crude extract specific antibody responses. sHZ significantly improved IgG levels (mainly IgG2c and IgG1) against Pf crude extract ( Figure 7A and data not shown).
To examine whether sHZ could be used in animal species other than mice, we immunized Beagle dogs with house dust mite allergen (Derf2) together with alum and sHZ, and boosted that elevated IgG2 type (but not IgG1) antibodies, which may resemble Th1-like immune responses in dogs ( Figure 7B and 7C) (Hou et al., 2006) . Accordingly, Derf2-specific IgE responses after Ag challenges were significantly reduced in sHZ coadministered dogs ( Figure 7C ). It is of note, however, that antibody 
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responses elicited in mice were dominant with IgG1 isotype, which was different from those in dogs ( Figure S5D ). These data further suggest that sHZ may serve as a potent Th1-like adjuvant, at least in the canine model, while it acts like a Th2-dominant adjuvant in a murine model.
DISCUSSION
Malaria is still one of the leading pathogens, affecting 40% of the world's population and killing over one million people each year, but a successful vaccine against it not yet available. Owing to the failure of many clinical trials for recombinant vaccines, and recent progress in our understanding of innate immune adjuvant effect of microbial products (Kaisho and Akira, 2002) , the wholeparasite vaccine strategy has been regaining attention (Good, 2009; Doolan et al., 2009 ). Successful vaccination with erythrocytic parasites was achieved using powerful adjuvants, such as CpG DNA (Su et al., 2003) . We further demonstrated that an increased dose of a crude extract of Pf parasites without adjuvant successfully displayed strong immunogenicity, owing to the enhanced ''built-in adjuvant'' activity of the parasite. Surprisingly, this adjuvant effect was heavily dependent on TLR9. Because this has been a matter of controversy, the TLR9 ligand in malaria parasite was carefully analyzed again, and we found that DNA is not required for this TLR9-mediated adjuvant effect of the Pf crude extract (Figure 2 ). It is thus reasonable to interpret that the built-in adjuvant in Pf crude extract is a non-DNA TLR9 ligand, such as HZ and/or some other heatlabile components as previously reported (Coban et al., 2005; Pichyangkul et al., 2004) . HZ is a heme crystalline dimer generated by parasite digestion of hemoglobin as a byproduct of the heme detoxification system in malaria infection (Arese and Schwarzer, 1997; Hanscheid et al., 2007) . It has been proposed to play important roles in pathophysiology during malaria infection, because it activates macrophages and dendritic cells to produce both proinflammatory and anti-inflammatory cytokines and chemokines (Engwerda and Good, 2005; Keller et al., 2006; Hanscheid et al., 2007; Coban et al., 2007a) . Although immune recognition of malarial HZ by TLR9 has been demonstrated in vitro and in vivo (Coban et al., 2005) , another study suggested that HZ itself was immunologically inert, and that TLR9-dependent immune activation is instead caused by HZ-conjugated malarial DNA (Parroche et al., 2007) .
Parroche et al. suggested that DNase-I treatment of Pf crude extract did not remove Plasmodium DNA from PfHZ shown by Pf-specific PCR (Parroche et al., 2007) . When we performed PCR by using the same Pf-specific primers, 205 bp PCR product of Pf DNA was completely lost after DNase-I treatment ( Figure S2B ). We further confirmed the absence of Pf DNA after treatment of Pf crude extract by PCR using the other primers (101 bp product) (data not shown). In vivo, this DNase-free Pf crude extract displayed potent adjuvant activity via TLR9 (Figure 2A ), strongly suggesting that the built-in adjuvant of Pf crude extract is not DNA.
What in Pf crude extract would be a TLR9 ligand rather than Pf DNA? We went on to reconfirm our previous finding that HZ is a TLR9 ligand by examining the definition of a ligand for a receptor, in which a ligand is to directly bind to a receptor in a specific manner. TLR9 binds directly both HZ and hemin, and change its conformation following binding to HZ (Figure 3) . Moreover, competition for TLR9 binding occurs among Pf crude extract, CpG DNA, and sHZ, further supporting the possibility that HZ fulfills the definition of TLR9 ligand specificity. We also identified the binding motifs in the extracellular domain of TLR9, where cysteine residues play a crucial role in controlling the binding to ligands including Pf crude extract, heme, and CpG DNA (Figure 4) . Taken together, these findings suggest that the adjuvant component of erythrocytic stage Pf parasites contains a TLR9 ligand, most likely HZ, but not DNA.
Involvement of the inflammasome pathways in inflammation during malaria infection, as has been implicated by a recent report (Orengo et al., 2008) , was not apparent in the built-in adjuvant effect of whole-parasite vaccination with erythrocytic stage Pf crude extract (Figure 1) . Consistently, the effect of synthetic HZ was also independent of the NLRP3-ASC inflammasome, as well as IL-1 receptor. It is of note that, while natural HZ in the Pf crude extract acts mostly as a TLR9 ligand, sHZ has an adjuvant effect independent of TLR9, but still utilizes the MyD88-dependent pathway. One possible explanation for this difference is that the uptake or ability to break the integrity of phagosomal and/or endosomal membrane of natural and synthetic HZ might differ given that the natural HZ is often covered by Pf-derived lipid, protein, or nucleic acids, compared with sHZ as a naked sharp crystal. Another explanation is that, although natural HZ purified from Pf cultures is known to be identical to sHZ (Pagola et al., 2000) , several purification protocols give different crystal sizes ranging from 50 nm to 20 mm, which displayed quite different adjuvant activities ( Figure 5 ). The studies are under investigation to examine whether different sizes of sHZ make distinct delivery and interaction with the innate immune cells and their immune receptors.
In addition, recent reports have suggested that immune recognition of and inflammatory response by sHZ is mediated by NLRP3 (Dostert et al., 2009; Griffith et al., 2009; Jaramillo et al., 2009) . Although all of these three reports showed that IL-1b production by macrophages as well as neutrophil recruitment in response to sHZ was reduced in mice lacking NLRP3, precise mechanism of NLRP3-inflammasome activation are yet unclear. Griffith et al. suggested that uric acid is induced by sHZ and that the uric acid is the NLRP3 ligand (Griffith et al., 2009 ), but Dostert et al. suggested that uric acid is not involved in NLRP3 activation by sHZ (Dostert et al., 2009 ). Moreover, Jaramillo et al. showed elegantly that sHZ activates Lyn/Syk-mediated intracellular signaling pathway at the upstream of NLRP3 or ASC, indicating the existence of other HZ receptor(s) such as Dectin1, TREM family members, Siglec, or DAP12 (Jaramillo et al., 2009) . Although the involvement of NLRP3 in sHZ-induced IL-1b or the following inflammatory response may play an important role in pathogenesis of malaria infections, we clearly demonstrate that NLRP3 as well as ASC, IL-1 receptor is not involved in sHZ-adjuvant activity (Figure 6 ), suggesting that there may be additional receptor(s) as well as pathway(s) for HZ-induced innate and adaptive immune activations.
Finally we found that sHZ acts as a potent adjuvant only when its synthesis method and size were optimized ( Figure 5 ). This adjuvant effect of HZ for protein vaccines was observed with different model antigens, such as OVA and HSA, and via different immunization routes, such as s.c. and i.n. immunization. It is of note that unlike CpG DNA, which has species-specific activity, HZ displayed its adjuvant effect in several animal models for vaccines, including murine, canine and non-human primate models (Figures 5-7 , data not shown). In mice, a predominantly IgG1-dominant antibody adjuvant effect observed after HZ-adjuvanted immunization and T cell specific immune responses were mainly IL-13 and IL-5, but not IFNg or IL-17, suggesting that HZ elicits Th2-type immune responses in mice (Figures 5,  6 , and S4). However, by contrast, dog immunization with HZ elicited IgG2-dominant antibody responses, which is considered a Th1-type immune response (Reed and Scott, 1993) . sHZ administration in the dog-allergy model was nonetheless very potent to reduce allergen-specific IgE responses (Figure 7) , suggesting successful usage of sHZ as an adjuvant in dogs against allergy. Similarly, our data suggested that sHZ could be introduced externally as an adjuvant to improve immunogenicity of whole-malaria vaccines ( Figure 7A ). Our preliminary data also suggest that, in non-human primates, sHZ could elevate malarial antigen-specific B and T cell responses, and could be used as a vaccine adjuvant for whole-blood stage vaccines (K.J.I., unpublished data). Overall, our results clearly show that HZ possesses inflammatory and adjuvant activities through differential regulation by TLR9 pathways, thereby potentiating its ability to act as a therapeutic target for treating malaria infection, and its usefulness in vaccine adjuvant development.
EXPERIMENTAL PROCEDURES Reagents
Hemin chloride was from Fluka (HPLC purified, >98% pure), whereas OVA and HSA (low endotoxin) were from Sigma. A synthetic CpG DNA (D35) was from Gene Design Incorporation. DNase-I was from Invitrogen. Zymosan was from Invivogen. MSU crystals were prepared as described elsewhere (Martinon et al., 2006) .
Mice and Immunizations
Mice deficient for MyD88, TLR9, Asc or Nlrp3, and Asc on a C57BL/6 background were generated and used for experiments as described previously (Coban et al., 2005; Franchi and Nunez, 2008 were immunized with a DNase-I-treated Pf crude extract. At 3 weeks after immunization, antibodies against Pf crude extract antigens in the sera of mice were detected by ELISA. Various immunization schedules were conducted using either OVA or HSA as antigens. For s.c. immunizations, mice were injected on day 0 with 50 mg OVA (or 10 mg HSA) in a total of 200 ml sHZ solution at various concentrations and boosted on day 10 with 25 mg OVA (or 10 mg HSA) in the same sHZ solution. Blood samples were collected from the mice on day 17 for analysis of OVA-or HSA-specific antibody responses. For i.n. immunizations, mice were anesthetized and administered i.n. with 5 mg OVA with or without 80 mg sHZ (15 ml/nose), twice, at 2-week intervals. The mice were sacrificed 10 days after the boost, and serum, bronchoalveolar lavage fluid, and nasal fluid secretion samples were collected for antibody measurements.
Dogs and Allergy Model
Five-month-old Beagle dogs from the breeding colony at Zenoaq Animal Experiment Center (Nippon Zenyaku Kogyo Co., Ltd., Fukushima, Japan) were used. All immunization and sensitization protocols were performed in accordance with the institutional guidelines of and approved by Zenoaq Animal Center Laboratories Committee. Dogs were immunized s.c. on day 0 with 100 mg Derf2 protein produced in silkworms by a recombinant Baculovirus system, formulated in 500 mg aluminum hydroxide in a 200 mg sHZ solution, and boosted on day 14 with the same dose. Four weeks after the boost immunization, dogs were challenged with Derf2 s.c. four times biweekly. Blood samples were collected on days 7, 14, 21, and 28 for analysis of Derf2-specific IgG1 and IgG2 antibody responses, and on day 90 for the measurement of antigen-specific IgE responses.
Preparation of Pf Crude Extract, Natural HZ, Synthetic HZ, and Pf DNA Mycoplasma-free Pf parasites (3D7) were maintained in culture medium as described previously (Aoki et al., 2002) . After synchronization, mature and HZ-rich mostly trophozoite and schizont stage parasites ($4%-5%) were purified by 63% Percoll density centrifugation, washed and resuspended in incomplete medium, freeze-thawed three or four times, and stored at À80 C until use. Each milliliter of HZ-rich Pf crude extract preparation contained approximately 1 3 10 9 infected erythrocytes. As controls, uninfected human erythrocytes were treated similarly. Pure natural HZ was extensively purified from Pf-infected erythrocytes as described previously (Coban et al., 2005) . Figure S5D . Experiments were repeated twice using four animals per group (**p < 0.01).
sHZ was purified from hemin chloride using two alternative methods (Egan, 2008) . Method 1 (acid-catalyzed method) is known to produce smaller and homogenous crystals and was performed as previously described (Coban et al., 2005; Jaramillo et al., 2005) . Briefly, 45 mg hemin chloride was dissolved in 4.5 ml 1 N NaOH and neutralized with 1 N HCl. Then, acetic acid was added until the pH reached 4.8, at a constant temperature of 60 C with magnetic stirring. The mixture was allowed to precipitate at room temperature overnight. The precipitate was subjected to washes with 2% SDS-buffered with 0.1 M sodium bicarbonate (pH 9.1) and subsequent extensive washes with 2% SDS, and then six to eight washes with distilled water. Method 2 (anhydrous method in methanol) is known to produce much bigger crystals and was performed as previously described (Bohle et al., 2002) . Briefly, hemin chloride (52.2 mg) was dissolved completely in 2 ml 2,6-lutidine L, diluted with 10 ml dimethyl sulfoxide:methanol (1:1 mixture), tightly wrapped with parafilm and left at room temperature for 2 weeks in the dark, before being centrifuged and washed with 10 ml 0.1 M NaHCO 3 for 3 hr. The final product was washed three times with water and methanol, and dried. A stock solution in distilled water was prepared for use in in vivo studies and stored at 4 C. The HZ concentration was calculated as either mM or mg/ml after weighing the dried amount of sHZ. Experiments were mostly performed with sHZ prepared by method 1, except for the results shown in Figure 5B . All solutions were prepared and resuspended in endotoxin-free water (double-processed tissue culture water, Sigma-W3500) and stored in the dark at 4 C. There was no detectable level of endotoxin by LAL assay in any HZ preparation. None of the sHZ purified had any other contaminants, such as hemin, as determined by TLC ( Figure S7A ) or protein/DNA determined by SDS-PAGE at pH 11 and agarose gel, respectively (data not shown). FT-IR and powder X-ray diffraction pattern of the sHZ confirmed that the sample showed the same unit cell parameters as reported previously (Pagola et al., 2000) ( Figures S7B and  S7C ). Pf genomic DNA was isolated as reported previously (Kongkasuriyachai et al., 2004) .
Recombinant TLR Proteins and Peptides
Recombinant fusion proteins consisting of the extracellular domains of the human TLRs TLR9 (amino acids 1-818) and TLR2 (amino acids 1-588) fused to mouse IgG2b-Fc were constructed by amplifying the corresponding extracellular domain and ligating the fragment in frame into a pCIneo vector containing the coding sequence for mouse IgG2b-Fc. Fusion proteins were stably expressed in 293-F cells and purified from cell lysates by protein G affinity chromatography. Peptides were derived from unique regions of human Tlr9 ectodomain sequence and synthesized by Operon Technologies.
Intraperitoneal Neutrophil Recruitment sHZ (1000 mg) was resuspended in 200 ml PBS and intraperitoneally administered to various mice. At 16-18 hr after injection, the peritoneum was washed with a 30 ml cold PBS containing EDTA (3 mM) and heparin (10 U/ml) and the cells were counted. Neutrophils were identified using PE-conjugated anti-Gr-1 and APC-conjugated anti-CD11b antibodies (Becton Dickinson) in the presence of an anti-CD16 antibody. The stained cells were washed and analyzed using a FACSCalibur system.
Antibody and Cytokine ELISA
The plates were coated with OVA (1 mg/ml) or HSA (10 mg/ml), Derf2 (1 mg/ml) or Pf SE36 antigen (3 mg/ml) and analyzed by ELISA using a previously described procedure (Coban et al., 2005; Okech et al., 2006) . Spleens were extracted 3 weeks after the prime immunization and then stimulated with Pf crude extract. Seventy-two hours later, the cell culture supernatants were collected and analyzed for IFNg, IL-13, IL-5, and IL-17 by ELISA (DuoSet ELISA Kit, R&D Systems).
Binding Assay and ELISA Zymosan (5 mg/ml), CpG DNA (D35; 10 mg/ml), Pf crude extract (10 mg/ml), and Pf DNA (2 mg/ml) were coated on 96-well plates in PBS overnight at 4 C and then blocked with PBS containing 1% bovine serum albumin. The binding of TLR9 or TLR2 fusion proteins was detected with HRP-labeled mouse antiIgG (Southern Biotech.). For competition ELISAs, rTLR9 protein was incubated with sHZ, MSU or CpG DNA for 1 hr and then incubated on Pf crude extractcoated plates for an additional 1 hr.
CD Spectroscopy
CD spectra were recorded with a J-820 spectropolarimeter (Jasco) using a 1 mm cell at 20 C. Each sample containing 1 mM TLR9 protein with or without a ligand (1 or 10 mM CpG DNA; 10 or 100 mM sHZ, or 10 or 100 mM MSU), was prepared in 20 mM sodium acetate buffer containing 150 mM NaCl at pH 5.5. Twenty spectra were acquired for each sample with a 1 nm bandwidth, a scanning speed of 50 nm per min, and a response time of 2 s, and then averaged. The resultant spectra were calculated after the spectra of rTLR9 were subtracted.
NMR Spectroscopy 1 H-1D NMR measurements were carried out using an AV400M NMR machine (Bruker BioSpin, Rheinstetten, Germany) with a 5 mm Shigemi tube (Shigemi, Tokyo, Japan) at 25 C. Each sample was prepared at a peptide concentration of 250 mM in 20 mM sodium phosphate buffer (pH 7.0) containing 10% (v/v) D 2 O for the signal lock. For the measurements with hemin, various concentrations of hemin were prepared and the pH was set to 7.0 to prevent precipitation of hemin. For the measurements with CpG DNA (D35), because the signals from CpG DNA were larger than those from the peptides, the spectrum of D35 was subtracted from the spectra of the peptide-CpG DNA mixture to more easily judge the difference. All NMR data were processed and analyzed using NMRPipe (Delaglio et al., 1995) and Igor Pro (WaveMetrics, Lake Oswego, OR).
FESEM and Particle Size Analysis
Slides were coated with different dilutions of sHZ and images were captured using ultra-high-resolution FESEM (S-4800; Hitachi). The particle size and distribution in the sHZ solution were analyzed using a laser-scattering particle size distribution analyzer (LA-950; Horiba).
Statistical Analysis
Statistical differences between groups were analyzed using the Student's t test.
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